Saturday, July 11, 2026

pharma · refractory hypotension in distributive shock

PAION Pharma

PAION Pharma is a pharma organization headquartered in EU. Primary therapeutic focus areas include refractory hypotension in distributive shock. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent

Aachen, DE HQ
2024 Founded
30 Employees
EMA registrant Type
Company details
Status
Public
HQ
Aachen, DE
Founded
2024
Employees
30
Programs
1
Drugs
6
Patents
0
Clinical program

CRH07

Phase 3 · small molecule · refractory hypotension in distributive shock

CRH07 for refractory hypotension in distributive shock is a Phase 3 program (small_molecule) at PAION Pharma GmbH with 1 ClinicalTrials.gov record(s).

← All PAION Pharma GmbH projects Phase 3 small molecule active

Internal code CRH07

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
PAION Pharma GmbH
Phase
Phase 3
Modality
small_molecule
Indication
refractory hypotension in distributive shock
Status
active
Trials
1